Literature DB >> 12019136

Antitrypanosomal activities of proteasome inhibitors.

Njinkeng Joseph Nkemngu1, Joseph Nkemgu-Njinkeng, Vera Rosenkranz, Michael Wink, Dietmar Steverding.   

Abstract

Seven peptidyl proteasome inhibitors were tested for in vitro activity against Trypanosoma brucei bloodstream forms. Two compounds showed activity in the low nanomolar range. In general, trypanosomes were more susceptible to the compounds than were human HL-60 cells. The data support the potential of proteasome inhibitors for rational antitrypanosomal drug development.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12019136      PMCID： PMC127253          DOI： 10.1128/AAC.46.6.2038-2040.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Programmed cell death in procyclic form Trypanosoma brucei rhodesiense --identification of differentially expressed genes during con A induced death.

Authors:  S C Welburn; S Lillico; N B Murphy
Journal:  Mem Inst Oswaldo Cruz       Date:  1999 Mar-Apr       Impact factor: 2.743

2.  Prohibitin and RACK homologues are up-regulated in trypanosomes induced to undergo apoptosis and in naturally occurring terminally differentiated forms.

Authors:  S C Welburn; N B Murphy
Journal:  Cell Death Differ       Date:  1998-07       Impact factor: 15.828

Review 3.  Proteasome inhibitors as anti-cancer agents.

Authors:  R Z Murray; C Norbury
Journal:  Anticancer Drugs       Date:  2000-07       Impact factor: 2.248

Review 4.  Structure and functions of the 20S and 26S proteasomes.

Authors:  O Coux; K Tanaka; A L Goldberg
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

5.  Activation of the cell death program by inhibition of proteasome function.

Authors:  H C Drexler
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

Review 6.  Ubiquitin proteasome pathway: implications and advances in cancer therapy.

Authors:  S A Shah; M W Potter; M P Callery
Journal:  Surg Oncol       Date:  2001 Jul-Aug       Impact factor: 3.279

7.  Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone.

Authors:  T A McCormack; A A Cruikshank; L Grenier; F D Melandri; S L Nunes; L Plamondon; R L Stein; L R Dick
Journal:  Biochemistry       Date:  1998-05-26       Impact factor: 3.162

8.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.

Authors:  K L Rock; C Gramm; L Rothstein; K Clark; R Stein; L Dick; D Hwang; A L Goldberg
Journal:  Cell       Date:  1994-09-09       Impact factor: 41.582

9.  Apoptosis in procyclic Trypanosoma brucei rhodesiense in vitro.

Authors:  S C Welburn; C Dale; D Ellis; R Beecroft; T W Pearson
Journal:  Cell Death Differ       Date:  1996-04       Impact factor: 15.828

10.  Inhibition of proteasome activity blocks cell cycle progression at specific phase boundaries in African trypanosomes.

Authors:  M C Mutomba; W Y To; W C Hyun; C C Wang
Journal:  Mol Biochem Parasitol       Date:  1997-12-15       Impact factor: 1.759
View more
  14 in total

1.  Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors.

Authors:  Dietmar Steverding; Robert W Spackman; Howard J Royle; Robert J Glenn
Journal:  Parasitol Res       Date:  2004-12-01       Impact factor: 2.289

2.  Case Report: Trypanosoma brucei Gambiense Human African Trypanosomiasis as the Cause of Fever in an Inpatient with Multiple Myeloma and HIV-1 Coinfection.

Authors:  Carl Boodman; Michael Libman; Momar Ndao; Cedric P Yansouni
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

3.  Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis.

Authors:  Bakela Nare; Stephen Wring; Cyrus Bacchi; Beth Beaudet; Tana Bowling; Reto Brun; Daitao Chen; Charles Ding; Yvonne Freund; Eric Gaukel; Ali Hussain; Kurt Jarnagin; Matthew Jenks; Marcel Kaiser; Luke Mercer; Elena Mejia; Andy Noe; Matt Orr; Robin Parham; Jacob Plattner; Ryan Randolph; Donna Rattendi; Cindy Rewerts; Jessica Sligar; Nigel Yarlett; Robert Don; Robert Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

4.  Inhibition of proteasome activity blocks Trypanosoma cruzi growth and metacyclogenesis.

Authors:  Josiane Cardoso; Maurilio J Soares; Rubem F S Menna-Barreto; Rozenn Le Bloas; Vanessa Sotomaior; Samuel Goldenberg; Marco A Krieger
Journal:  Parasitol Res       Date:  2008-06-26       Impact factor: 2.289

Review 5.  Antiparasitic chemotherapy: from genomes to mechanisms.

Authors:  David Horn; Manoj T Duraisingh
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-09-11       Impact factor: 13.820

6.  Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas' Disease.

Authors:  Marta L Lima; Lindsay B Tulloch; Victoriano Corpas-Lopez; Sandra Carvalho; Richard J Wall; Rachel Milne; Eva Rico; Stephen Patterson; Ian H Gilbert; Sonia Moniz; Lorna MacLean; Leah S Torrie; Carmine Morgillo; David Horn; Fabio Zuccotto; Susan Wyllie
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

7.  Targeting essential pathways in trypanosomatids gives insights into protozoan mechanisms of cell death.

Authors:  Despina Smirlis; Michael Duszenko; Antonio Jiménez Ruiz; Effie Scoulica; Patrick Bastien; Nicolas Fasel; Ketty Soteriadou
Journal:  Parasit Vectors       Date:  2010-11-17       Impact factor: 3.876

8.  Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B.

Authors:  Jennifer M Reynolds; Kamal El Bissati; Jens Brandenburg; Arthur Günzl; Choukri Ben Mamoun
Journal:  BMC Clin Pharmacol       Date:  2007-10-23

9.  Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib.

Authors:  Dietmar Steverding; Xia Wang
Journal:  Parasit Vectors       Date:  2009-07-07       Impact factor: 3.876

10.  Cell communication and protein degradation: All in one parasitic package.

Authors:  Michal Sharon; Neta Regev-Rudzki
Journal:  J Extracell Vesicles       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.